NECTAR7 Launches NIAGEN® & Collagen Dietary Supplement

Imprimer
| Source : ChromaDex Corporation

IRVINE, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXCD) (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that NECTAR7 has released a new product, NIAGEN® & COLLAGEN featuring ChromaDex’s lead ingredient, NIAGEN®.

Jeromy Stallings, President of NECTAR7 Media commented, “NECTAR is excited about launching the first and only NIAGEN® & Collagen anti-aging nutricosmetic under the NECTAR7 brand. Most people are unaware that collagen production decreases approximately 1.5% per year starting around age 25. More importantly, science has shown that collagen production is NAD+ dependent.  NIAGEN®, a major ingredient in the NECTAR7 exclusive formula, has been shown in a recent human trial to increase NAD+.” NECTAR7 nutricosmetics are available at www.NECTAR7.com.

Frank Jaksch Jr., founder and CEO of ChromaDex, commented, “We are proud to add NECTAR7 to the growing list of customers for NIAGEN®, our branded nicotinamide riboside.”

ChromaDex’s ingredient NIAGEN®, is the first and only commercially available form of nicotinamide riboside (NR), a naturally occurring vitamin B3 metabolite found in milk. In addition to human clinical studies, ChromaDex is actively collaborating with numerous leading universities and research institutes studying the health benefits of NIAGEN®.

In August 2015, ChromaDex announced results from the first human clinical study which demonstrated that a single dose of NIAGEN® can elevate the co-enzyme NAD+ in the blood by as much as 2.7-fold and was safe.  The results of that study constituted a significant milestone as it showed for the first time an increase in NAD+ in humans has been demonstrated through NR supplementation.

About Nicotinamide Riboside (NR)

Published research has shown that NR is perhaps the most effective precursor to boost the co-enzyme NAD+ in the cell. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy. In recent years, NAD+ has been shown to be essential in supporting healthy cellular metabolism, including the efficient conversion of blood glucose into energy.

As organisms age, NAD+ levels drop, which leads to a decrease in mitochondrial health; this in turn leads to age-related health issues. Low NAD+ levels limit activity of a group of enzymes called sirtuins, which are believed to play a key role in longevity. NAD+ levels can be depleted by lifestyle choices such as overeating and lack of exercise. By boosting NAD+, NR can increase mitochondrial health and induce creation of new mitochondria.

About NECTAR7:

NECTAR7, LLC is a global company that brings life-enhancing, science-based nutrition and lifestyle supplements to market. Its products are based on the latest scientific studies and breakthroughs. Backed by science and some of the world’s leading researchers, NECTAR7 markets performance-based nutritional supplements to help people improve healthspan. To learn more about NECTAR7, please visit https://www.nectar7.com/.

About ChromaDex:

ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; ProC3G®, a natural black rice containing cyanidin-3-glucoside; IMMULINA, a spirulina extract; and Purple Corn derived from a proprietary non-GMO purple corn hybrid which contains an extraordinarily high level of anthocyanins. To learn more about ChromaDex, please visit www.ChromaDex.com.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2016, the Company’s Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

ChromaDex Company Contact:

Andrew Johnson
Director of Investor Relations
949-419-0288
andrewj@chromadex.com

ChromaDex Investor Contacts:

The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com